Tag: Cagent Vascular

Sectoral Asset Management makes US$9 million investment into Cagent Vascular

Cagent Vascular recently announced the investment of US$9 million by Sectoral Asset Management. Along with the investment, Marc-Andre Marcotte has joined the board of...

LINC 2021: PRELUDE-BTK results confirm Serranator device novel mechanism of action

Cagent Vascular announced the results of its PRELUDE-BTK study at LINC 2021 (The Leipzig Interventional Course; 25–29 January, online). The PRELUDE-BTK study was a...
Serranator Alto

Cagent Vascular raises US$11.87M funding

Cagent Vascular has announced the completion of US$11.87 million in Series B funding. The round was led by two strategic investors including one that...
Serranator Alto

Serrenator Alto first-in-man PRELUDE study results presented at LINC 2018

Cagent Vascular, a developer of technology for vessel dilatation in cardiovascular interventions, has announced positive results from the first-in-human PRELUDE study of the company's...

Serranator Alto serration balloon effective at 30 days in treating critical...

Preliminary 30-day data from the PRELUDE trial investigating the use of the Serranator Alto percutaneous transluminal angioplasty (PTA) serration balloon catheter (Cagent Vascular) have...

Cagent Vascular completes enrolment of PRELUDE study using Serranator Alto device

Cagent Vascular has announced the completion of enrolment in the first-in-human PRELUDE study. The purpose of this prospective, single-arm, multicentre feasibility study is to...

Cagent Vascular announces FDA 510(k) clearance of Serranator Alto serration balloon...

Cagent Vascular has announced US Food and Drug Administration 510(k) clearance of its lead product, the Serranator Alto percutaneous transluminal angioplasty serration balloon catheter. The Serranator...